<DOC>
	<DOCNO>NCT02182570</DOCNO>
	<brief_summary>The safety efficacy WAL 801 CL ( epinastine hydrochloride ) Dry Syrup treatment atopic dermatitis child evaluate plasma drug concentration measure .</brief_summary>
	<brief_title>WAL 801 CL Dry Syrup Pediatric Atopic Dermatitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Epinastine</mesh_term>
	<criteria>For inclusion study , subject must pediatric atopic dermatitis patient meet follow criterion thus appropriate observation pruritus . Diagnosis atopic dermatitis conduct accordance `` Definition Diagnostic Criteria Atopic Dermatitis '' , issue Japanese Dermatological Association . 15 year age young Body weight 14 kg Outpatients The patient undergoing treatment `` strong '' lowergrade external steroid preparation &gt; = 1 week time inform consent obtain Pruritus `` 2 '' high grade start time administration Use sustain release adrenocorticotropic hormone ( Kenacort® A , Depomedrol® , etc . ) , oral preparation methotrexate , oral preparation ciclosporin , within 4 week initial administration investigational product Oral intake , inhalation injection steroid within 2 week initial administration investigational product Use external steroid preparation `` Strongest '' sit face scalp within 2 week initial administration investigational product Undergoing phototherapy Undergoing specific desensitization therapy modulation therapy Past history contact dermatitis cause external steroid preparation Possibility exacerbation external steroid preparation infectious skin disease cause bacteria , fungi , virus Clinically significant hepatic , renal , cardiac disease complication : therefore , judgement patient ineligible inclusion study . Patients must exclude study patient fell Grade 2 , MHW ( Ministry health welfare ) Adverse Reaction Severity Classification Criteria Past history allergy drug Participation clinical study , history participation clinical study within 6 month date patient give consent participate study Judgement Principal Investigator Investigator patient ineligible inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>